[{"orgOrder":0,"company":"Inoviv","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Inoviv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inoviv \/ Hoxton Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Inoviv \/ Hoxton Ventures"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"HER-096","moa":"CDNF","graph1":"Neurology","graph2":"Phase I","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Herantis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Herantis Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for HER-096

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Forum
                          Not Confirmed
                          Peptide Forum
                          Not Confirmed

                          Details : HER-096 is a CDNF mimetic that has the potential to protect against the neuronal degeneration and cell death that cause the symptoms of Parkinson’s disease.

                          Product Name : HER-096

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 13, 2025

                          Lead Product(s) : HER-096

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Forum
                          Not Confirmed
                          Peptide Forum
                          Not Confirmed

                          Details : The net proceeds will be used to accelerate company's drug development pipelines, including HER-096, developed from neurotrophic factor CDNF, a groundbreaking approach to Parkinson's disease.

                          Product Name : HER-096

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : HER-096

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Hoxton Ventures

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank